You are hereArticles

Articles


ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF TOLPERISONE HYDROCHLORIDE AND DICLOFENAC SODIUM IN BULK AND PHARMACEUTICAL FORMULATION

ABOUT AUTHORS:
Akash M Patel*, Nirav N Patel, Prakash A Sathwara
*Faculty of Pharmacy, Dharmsinh Desai University,
Nadiad, Gujarat
Aku.pharmacy@gmail.com

ABSTRACT
Quantitative analysis of any drug is an important tool in an industry. It is important to determine that the raw material, intermediate products as well as final products meet its specifications and are of required quality. The number of drugs and drug formulations introduced into the market has been increasing at an alarming rate. These drugs or formulations may be either new entities or partial structural modification of the existing ones or novel dosage forms.

Spectrophotometry and HPLC methods are considered to be most suitable for estimation of the drugs present in pharmaceutical dosage forms.

· Literature review reveals that several spectroscopic and Chromatographic method have been reported for estimation of TOL and DIC alone as well as with other drugs.
· Simultaneous equation, dual wavelength difference UV spectrophotometry and First derivative spectroscopic method is available for this combination.
· The aim of work is to develop and validate cost effective First derivative method in water and RP-HPLC method for simultaneous estimation of TOL and DIC in bulk and Tablet dosage form.
· Development of UV spectrophotometric method.


METHOD VALIDATION OF ANALYTICAL PROCEDURES

ABOUT AUTHORS
Prakash Chanda Gupta
QC Executive,
National Healthcare Pvt. Ltd., Nepal
p_c_gupta@yahoo.com

ABSTRACT
After the development of an analytical procedure, it is must important to assure that the procedure will consistently produce the intended a precise result with high degree of accuracy. The method should give a specific result that may not be affected by external matters. This creates a requirement to validate the analytical procedures. The validation procedures consists of some characteristics parameters that makes the method acceptable with addition of statistical tools.


ROLE OF BCG IN TREATMENT OF BLADDER CANCER

ABOUT AUTHOR
Abhishek Singhal
Department of Pharmacology,
Smt. Kashibai Navale College of Pharmacy, Kondhwa (Bk.),
Pune, Maharastra, India
* abhishekspharma@gmail.com

ABSTRACT
Aim: This review is written to describe the role of immunotherapy in cancer treatment.
Annually, 13,000 deaths result from bladder cancer. Since the first report of intravesical use of BCG in 1976, investigators try to understand the working mechanism of BCG as an antitumour modality. Arbitrarily, BCG therapy consists of a single course of six weekly intravesical instillations. Bacillus Calmette-Gue´rin, an attenuated strain of Mycobacterium bovis, was developed by Calmette and Gue´rin with the intention to generate a vaccine against tuberculosis. Extension of BCG treatment (maintenance immunotherapy) is used to increase efficacy.
Results of various experiments describe that after instillation in the bladder, BCG accumulates near the bladder wall and is internalised and processed by professional antigen-presenting cells (APCs) and (high-grade) tumour cells. Then BCG antigens are presented to CD4+ T cells. Then local synthesis of a particular set of cytokines or cell-mediated immune response. NK cells may be involve in tumour cell killing.


DEADLY BUT CURABLE: A REVIEW ON POTENTIAL TREATMENTS FOR EBOLA HAEMORRHAGIC FEVER

ABOUT AUTHOR:
Bushra Shamim
Department of Pharmaceutics,
Faculty of Pharmacy,
Hamdard University, New Delhi, India
bushrashamim21@gmail.com

ABSTRACT
This is a review article on potential treatments for Ebola virus disease, also known as Ebola haemorrhagic fever. Ebola fever has emerged as one of the deadliest known forms of hemorrhagic fever since discovered in 1976.  Transmission among humans occurs through the exchange of blood and body secretions. The Ebola virus causes an acute, serious illness which is often fatal if untreated. In this article experimental treatments like blood, immunological and drug therapies are discussed that are under development


STANDARDIZATION OF IMPORAL, VIVATI AND TEERANKOTTAI LEHYAMS

ABOUT AUTHORS:
P. Devi1, R. Meera2*, P. Rajasoundarapandian2, Madhavanmallayasamy2
1Department of pharmacognosy, K.M.College of pharmacy,
2Researcher, Radianz, Healthcare private Limited,
Madurai, Tamil Nadu, India.
*meeraharsa23@gmail.com

ABSTRACT
Objective:
Imporal, Vivati and Teerankottai Lehyams were prepared by ayurvedic formulary and were analysed.
Materials and Methods:
Lehyams conjunction with ingredients such as kadukkai, tetrankottai, chebula, impural, verpatti, pacum pal, panankarkantu, catipattiri, valmilaku,catikkay, terrankottai, tipple, milakucukku, kadukkai, tanrikkay, cirrarakottai, nellikkay, cirakam, carkkarai, honey and ghee in different proportions.
Results:
The Loss on drying, Total ash, Acid insoluble ash, Alcohol soluble extractive, Water soluble extractive, Saponification value and Sugar content were determined respectively. The preliminary phyto chemical investigation shows the presence of alkaloids, carbohydrates, glycosides, saponin, tannins and flavonoids.
Conclusion:
Increase the medicinal properties against appetizer, cough and tuberculosis by preparing like this herbal products.


BIOSIMILARS: SCALE UP FROM R&D TO COMMERCIAL STAGE

ABOUT AUTHOR:
Madhusudan P Dabhole
Group Manager - BioProcess,
Richcore Life Sciences Ltd, Bangalore, Karnataka, India.
madhav888@rediffmail.com

ABSTRACT
The scale up of recombinant proteins involves a multi- dynamic strategic approach to achieve maximum output consistently. Various parameters during the fermentation will limit the synthesis of desired protein, which otherwise can be produced with ease in case of classical fermentation. In order to synthesis the protein, it is very important to understand the process at laboratory scale – both from scale up point of view and productivity improvement at large scale. Some of this parameters and scale up parameters are discussed below in this review.


DEVELOPMENT, CHARACTERISATION AND INVITRO EVALUATION OF BUCCOADHESIVE BILAYERED TABLETS FOR THE TREATMENT OF HYPERTENSION

ABOUT AUTHORS:
Kavitha Reddy Jupally*, A.Pavani, R. Raja Reddy, Habibuddin.
Department of Pharmaceutics, Malla Reddy Pharmacy College,
Maisammaguda (via- Hakimpet), secunderabad, Telangana, India.
kavithareddy0811@gmail.com

ABSTRACT
Ramipril is a prodrug belonging to the class of angiotensin-converting enzyme (ACE) inhibitor, which undergoes extensive hepatic first pass metabolism. The aim of the present study is to develop buccoadhesive bilayered tablet of ramipril  to achieve the greater therapeutic efficacy, to increase the bioavailability, to overcome the first pass hepatic metabolism of the drug. A UV spectrophotometric method has been employed for the estimation of Ramipril at 219 nm. Buccal tablets of Ramipril were prepared by direct compression method using ethyl cellulose as a polymer. The precompression parameters like bulk density, tapped density, carr’s index and angle of repose were determined. The post compression parameters like hardness, thickness, friability, weight variation, in vitro dissolution, FTIR studies were carried out to check if any interactions had occurred, results were promising. The optimized formulation was selected based on results and percentage drug release was found to be 92.95 and followed First order, peppas model with Fickian release mechanism.


A BRIEF REVIEW ON SUSTAINED RELEASE MATRIX TABLETS OF BACLOFEN

ABOUT AUTHORS:
Singh Surya Pratap*, Soni Shankar Lal, Khinchi Mahaveer Prasad, Gulia Ritu, Namdev Abhisek
Department of pharmaceutics, Kota College of  Pharmacy,
Ranpur, Kota, Rajasthan, India
sp.kota91@gmail.com

ABSTRACT
The objective of the present study was to focus on sustained release matrix tablets of baclofen, for treatment of spastically resulting from multiple sclerosis, flexor spasm and muscular rigidity. Designing effective therapies for Spinal cord injury (SCI) has been a challenging problem because spinal cord injuries are heterogeneous in causality, severity and location of injury.

Effective drug therapy for Spinal cord injury (SCI) first became a reality in 1990 with the finding that the steroid drug methylprednisolone(MP) can significantly improve recovery. Significant advances in recent year, including an effective drug therapy for acute SCI, have improve recovery. In spinal cord injury, pain persist for longer period i.e., several months, hence the long-term treatment is necessary for maintaining the drug concentration in the therapeutic range.

Hence, there is a need of sustained release dosage form. Baclofen,4-amino-3-(4-chlorophenyl)-butyric acid is another structural analog of GABA, which is widely used now a days in the treatment of multiple sclerosis, flexor spasms, muscular rigidity. spinal cord injuries and other spinal cord diseases.


EFFECT OF MAGNETIC FIELD ON CANCER CELLS

ABOUT AUTHORS:
Rajesh Tiwari1*, Roshan kumar2
1Chemistry Department, Dr. Ghanshyam Singh Post Graduate College, Varanasi
2SBCBE VIT University, Vellore
*Rajesh.tiwari851@gmail.com

ABSTRACT
In 16th century physician were of the opinion that magnet can be used for the treatment or eliminate the diseases from the body. Here the reports about the chemical synthesis, protection, functionalization and application of magnetic nanoparticles of nano structured system. Research of magnetic nanoparticles for targeted drug delivery system and function of magnetic nanoparticles on particular area are reviewed. Use of magnetic nanoparticles for cancer diagnosis has been advancing day by day. This review is related to the multifunctional use of magnetic nanoparticles probes and their use in bio imaging and nano medicine.


MULTIPLE SCLEROSIS: OVERVIEW ON SIMPLE CURE

ABOUT AUTHORS:
Duvvuru Ashok Kumar1*, Languluri Reddenna2
1Department of Pharm-D, P. Rami Reddy Memorial College of Pharmacy, Kadapa, Andhra Pradesh, India
2Department of Pharmacy Practice, Rajiv Gandhi Institute of Medical Sciences, Kadapa, Andhra Pradesh, India
ashok.alex11@gmail.com

ABSTRACT
MS is the most common inflammatory-demyelinating disease of the central nervous system (CNS). MS is estimated to affect 400,000 persons in the United States and 2 million people worldwide. Women are affected twice as frequently as men, between the ages of 20 and 40. The etiology of MS is still unknown, but according to current data the disease develops in genetically susceptible individuals and may require additional environmental triggers. In this paper, we present the insight on simple cure for multiple sclerosis.